NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Rhythm Pharmaceuticals, Inc. RYTM
11 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$189.8M
▲ 45.8% vs FY2024
EPS · FY25
$-3.11
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-244.5%
Net margin · FY25
-103.6%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 189.8M
Revenue, FY2025 · full 11-year series below
Revenue
Net income
The company lost 104 cents on every revenue dollar this year.
Per share
USD -3.11
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-244.5%
Return on equity, FY2025
ROE
Operating margin-101.2%
Net margin-103.6%
Return on assets-45.1%
Each USD of equity lost 244 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+100.2%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.07B
Shares outstanding, FY2025
Change, 5 years+51.9%
Change, 10 years—
The share count grew 52% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 480.2M
total assets, end of FY2025
Total assetsUSD 480.2M
EquityUSD 139.1M
CashUSD 54.3M
Gross debtUSD 108.2M
Net debtUSD 53.9M
Current ratio4.41×
Net debt stands at 39% of equity.
History
11 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
Revenue $B
0.2
0.1
0.1
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
Operating income $B
−0.2
−0.3
−0.2
−0.2
−0.2
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
EBITDA $B
−0.2
−0.3
−0.2
−0.2
−0.2
−0.1
−0.1
−0.1
−0.0
−0.0
·
Income tax $B
0.0
0.0
0.0
·
·
·
·
·
·
·
·
Net income $B
−0.2
−0.3
−0.2
−0.2
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
EPS, diluted $
−3.11
−4.34
−3.20
−3.47
−1.40
−3.04
−3.86
−2.39
−2.83
−2.85
−1.18
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
ROE %
−244.5
−272.2
−85.1
−66.1
−30.9
−59.9
−53.4
−37.9
−60.1
·
·
Shares out B
0.07
0.06
0.06
0.06
0.05
0.04
0.04
0.03
0.03
0.01
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
31 of 31
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed